| amphotericin b liposome / Generic mfg. |
ACTRN12612000367842: Feasibility of using single dose liposomal Amphotericin B for the treatment of Visceral Leishmaniasis in Bangladesh |
|
|
| Recruiting | 4 | 300 | | | World Health Organization, World Health Organization | Visceral leishmaniasis | | | | |
2008-008382-35: Open , multicenter, randomized trial comparing two therapeutic approaches for the treatment of invasive fungal infections in neutropenic onco-hematologic patients.Empiric vs. ``presumptive`` (preemptive) antifungal therapy. |
|
|
| Ongoing | 4 | 270 | Europe | Solution for infusion, Powder and solvent for solution for infusion, ABELCET, CANCIDAS, AMBISOME | Azienda Ospedaliera di Perugia | opportunistic fungal infections in neutropenic onco-hematologic patients | | | | |
2007-001795-37: WIRKORTKONZENTRATIONEN VON AMPHOTERICIN B FORMULIERUNGEN IN ASZITES, LIQUOR, PLEURAERGUSS, GALLE UND LIQUOR BEI KRITISCH KRANKEN(Target-site concentrations of Amphotericin B preparations in ascites, pleural effusion, bile and cerebrospinal fluid in critically ill patients) |
|
|
| Ongoing | 4 | 24 | Europe | Amphocil, AmBisome, Abelcet, Amphotericin B \"BMS\", ABCD, LAMB, ABLC, AMB, Amphocil, AmBisome, Abelcet, Amphotericin B \"BMS\", Amphocil, AmBisome, Abelcet, Amphotericin B \"BMS\" | Medical University Innsbruck, Dpt. Internal Medicine, Div. Internal Medicine | Plasma and target-site (ascites, pleural effusion, bile and cerebrospinal fluid) concentrations of amphotericin B preparations will be measured in critically ill patients, requiring treatment with a amphotericin b preparation and requiring pleuracentesis, abdominal paracentesis, lumbar puncture or bile sampling for diagnostic or therapeutic reasons, to determine penetration of the drugs to target site. | | | | |
2005-003406-28: Pharmakokinetik von lipid-formuliertem Amphotericin B unter Albumindialyse(Pharmacokinetics of lipid-formulated amphotericin B during albumin dialysis) |
|
|
| Ongoing | 4 | 12 | Europe | Amphocil, AmBisome, Abelcet, ABCD / LAMB / ABLC, Amphocil, AmBisome, Abelcet, Amphocil, AmBisome, Abelcet | Medical University, Dpt. Internal Medicin, Division of General Inteal Medicine | Plasma concentrations of lipidformulated amphotericin B will be measured in patients requiring treatment with lipid-formulated amphotericin B for systemic fungal infection (proven or suspected) and impaired renal function as well as albumin dialysis for cholestatic liver failure. | | | | |
2005-003609-96: Amphotericin B Spiegel in bronchoalveolären Lavagen (Epithelial Lining Fluid) unter Behandlung mit lipidformuliertem Amphotericin B(Amphotericin B levels in broncho-alveolar lavage [epithelial lining fluid] during treatment with lipid-formulated amphotericin B) |
|
|
| Ongoing | 4 | 45 | Europe | Amphocil, AmBisome, Abelcet, ABCD / LAMB / ABLC, Amphocil, AmBisome, Abelcet, Amphocil, AmBisome, Abelcet | Medical University, Dpt. Internal Medicin, Division of General Internal Medicine | Plasma and ELF concentrations of lipidformulatied amphotericin b will be measured in patients requiring treatment with lipid-formulated amphotericin B for fungal pneumonia (proven or suspected). | | | | |
2015-001566-26: A B-D-GLUCAN DRIVEN ANTIFUNGAL STEWARDSHIP APPROACH TO MANAGE EMPIRICAL THERAPY IN PATIENTS AT VERY HIGH RISK FOR INVASIVE CANDIDIASIS: A RANDOMIZED CONTROLLED TRIAL Una strategia di governo della terapia antifungina guidata da determinazioni seriate del BETA-D-GLUCANO (BDG) in una popolazione di pazienti ad alto rischio per candidiasi invasiva: studio controllato randomizzato |
|
|
| Ongoing | 4 | 180 | Europe | TYGACIL, merrem, Tazocin, cancidas, ecalta, ambisome, TYGACIL, merrem, tazocin, cancidas, ecalta, ambisome, Powder for solution for infusion, Powder for solution for injection, TYGACIL - 50 MG POLVERE PER SOLUZIONE PER INFUSIONE 10 FLACONCINI DI VETRO 5 ML, MERREM - 500 MG POLVERE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 10 FLACONCINI, TAZOCIN - 4 G + 0.500 G POLVERE PER SOLUZIONE PER INFUSIONE 12 FLACONCINI DI POLVERE, CANCIDAS - 50 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE ENDOVENOSA 1 FLACONCINO 10 ML, ECALTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO-FLACONCINO (VETRO) DA 30 ML 1 FLACONCINO, AMBISOME - 50 MG POLVERE PER SOLUZIONE PER INFUSIONE 10 FLACONCINI | AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, AOU di Bologna (fondi per la ricerca) | invasive candidiasis candidiasi invasiva, invasive candidiasis candidiasi invasiva, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2017-001433-74: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort |
|
|
| Completed | 4 | 40 | Europe | Powder for concentrate for dispersion for infusion, Powder for solution for infusion, AmBisome Liposomal Amphotericin B 50mg Powder for Concentrate for Dispersion for Infusion., ECALTA 100 mg powder for concentrate for solution for infusion, CANCIDAS 50 mg powder for concentrate for solution for infusion, Diflucan 150 mg hard capsules, CRESEMBA 200 mg powder for concentrate for solution for infusion, Mycamine 50 mg powder for solution for infusion, Noxafil® 300 mg concentrate for solution for infusion, Voriconazole 200 mg powder for solution for infusion | CHU de NIMES, CHU NIMES | The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, Not possible to specify | | | | |
2007-001924-11: Primary fungal profilaxis with Liposomal Amphotericin B at the dose of 10 mg/kg a week in adult patient undergoing orthotopic liver transplantation and high risk for postoperative fungal infection: a prospective study |
|
|
| Ongoing | 3 | 30 | Europe | AMBISOME*INFUS 10FL LIOF 50MG, AMBISOME*INFUS 10FL LIOF 50MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | Postoperative fungal infection. | | | | |
2018-000972-14: Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmonary Aspergillosis: a prospective, randomized, single blind study, (single aspergilloma excluded). |
|
|
| Not yet recruiting | 3 | 224 | Europe | Ambisome®, Sporanox®, Vfend®, NOXAFIL, Powder for solution for infusion, Capsule, Tablet, Ambisome®, Sporanox®, Vfend®, NOXAFIL | CHU DE POITIERS, DGOS, JASSEN, MSD-MERCK, PFIZER, ELIVIE, SOS-Oxygen, VIVISOL, ORHE PHARMA | Chronic Pulmonary Aspergillosis, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | | | | |
2016-002335-14: A ß-d-glucan guided antifungal stewardship strategy for the management of patients with severe abdominal sepsis. A multicenter interventional explorative study with a pharmadynamic/pharmachokinetic substudy entitled: “A Pilot substudy of Liposomal Amphotericin B Pharmacodynamics in Patients with Abdominal Sepsis” conducted only in the coordinating center Strategia di gestione antimicotica guidata dal ß -d-glucano per pazienti con sepsi addominale grave. Studio interventistico multicentrico esplorativo con sottostudio di farmacocinetica/farmacodinamica intitolato: “Sottostudio pilota di farmacodinamica di amfotericina B liposomiale in pazienti con sepsi addominale” che verrà condotto solo nel centro coordinatore |
|
|
| Ongoing | 3 | 40 | Europe | AmBisome, [AmBisome], Powder for solution for infusion, AMBISOME - 50 MG POLVERE PER SOLUZIONE PER INFUSIONE 10 FLACONCINI | AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, Gilead | Patients with severe sepsis or septic shock Pazienti con patologia chirurgica addominale severa; Pazienti con sepsi grave o shock settico, Patients with severe sepsis or septic shock Pazienti con patologia chirurgica addominale severa; Pazienti con sepsi grave o shock settico, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2021-000386-32: A study to evaluate the efficacy and safety of olorofim versus AmBisome® for treatment of invasive aspergillosis. Estudio para evaluar la eficacia y seguridad de olorofim en comparación con AmBisome® para el tratamiento de la aspergilosis invasiva. |
|
|
| Not yet recruiting | 3 | 225 | Europe | olorofim, AmBisome, F901318, Film-coated tablet, Powder for concentrate for dispersion for infusion, AmBisome | F2G Ltd., F2G Ltd. | invasive fungal infections due to Aspergillus spp. infecciones fúngicas invasivas debidas a Aspergillus spp., invasive fungal infections infecciones fúngicas invasivas, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
NCT05108545: A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever |
|
|
| Not yet recruiting | 3 | 93 | NA | Amphotericin B liposomes | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Neutropenia and Fever | 07/22 | 01/23 | | |
| Recruiting | 3 | 120 | RoW | Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B | Fundacion Nacional de Dermatologia, Hospital Dermatologico de Jorochito, Centro Nacional de Enfermedades Tropicales CENETROP, ABF Foundation for Medical Research | Mucosal Leishmaniasis | 04/24 | 11/24 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Not yet recruiting | 3 | 254 | RoW | Single high dose of liposomal amphotericin B, L-AmB single high dose investigational arm, L-AmB standard dose, L-AmB conventional therapy | Federal University of Health Science of Porto Alegre | Disseminated Histoplasma Capsulatum Infection, AIDS and Infections, Immunosuppression, Fungal Infection | 05/25 | 05/26 | | |
NCT03656081: Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole |
|
|
| Recruiting | 3 | 224 | Europe | inhaled Ambisome®, inhaled placebo, placebo (for Ambisome®), Itraconazole, Sporanox® | Poitiers University Hospital | Chronic Pulmonary Aspergillosis | 06/27 | 12/29 | | |
ACTRN12609001029280: Liposomal amphotericin B for the treatment of Bangladeshi patients with visceral leishmaniasis. |
|
|
| Active, not recruiting | 2/3 | 35 | | | The United Nations Children's Fund (UNICEF)/ The United Nations Development Programme (UNDP) /World Bank /World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases (TDR), The United Nations Children's Fund (UNICEF)/ The United Nations Development Programme (UNDP) /World Bank /World Health Organization (WHO) Special Programme for Research and Training in Tropical Diseases (TDR) | Visceral leishmaniasis (VL) | | | | |
NCT06040489: Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly |
|
|
| Recruiting | 2/3 | 100 | RoW | Miltefosine 50mg, Pentoxifylline 400mg, Liposomal Amphotericin B | University of Brasilia | Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous | 06/24 | 06/26 | | |
| Recruiting | 2/3 | 356 | RoW | Single dose liposomal Amphotericin and Fluconazole, AMBISOME and fluconazole, Fluconazole | Makerere University, University of Minnesota, Gilead Sciences | Cryptococcal Meningitis | 10/27 | 04/28 | | |
2011-001845-34: LIPOSOMAL AMPHOTERICIN B (AMBISOME) 10 mg/kg once a week for 10 weeks as maintenance antifungal therapy for Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leukaemia and/or in Allogeneic Hematopoietic Stem Cell Transplant recipients. AMFOTERICINA B liposomiale (Ambisome ) 10 mg/kg una volta alla settimana per 10 settimane come terapia di mantenimento per infezioni fungine invasive certe/probabilili in pazienti ematologici con leucemia mieloide acuta e/o in pazienti con trapianto di cellule staminali allogeniche |
|
|
| Ongoing | 2 | 87 | Europe | Powder for infusion, AMBISOME*INFUS 10FL LIOF 50MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, GILEAD | Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leukaemia and/or in Allogeneic Hematopoietic Stem Cell Transplant recipients. infezioni fungine invasive certe/probabilili in pazienti ematologici con leucemia mieloide acuta e/o in pazienti con trapianto di cellule staminali allogeniche, Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leukaemia and/or in Allogeneic Hematopoietic Stem Cell Transplant recipients. infezioni fungine invasive certe/probabilili in pazienti ematologici con leucemia mieloide acuta e/o in pazienti con trapianto di cellule staminali allogeniche, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
NCT04059770: Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients |
|
|
| Completed | 2 | 99 | RoW | single dose of L-AmB, Intervention 1, 2 doses of L-AmB, Intervention 2, 2 weeks of L-AmB, Intervention 3 | Alessandro Pasqualotto, Hospital de Clinicas de Porto Alegre, Hospital Nossa Senhora da Conceicao, Irmandade Santa Casa de Misericórdia de Porto Alegre | Histoplasmosis, AIDS | 12/21 | 03/22 | | |
NCT05468372: Amphotericin Versus Posaconazole for Pulmonary Mucormycosis |
|
|
| Recruiting | 2 | 30 | RoW | Posaconazole 600 mg followed by posaconazole 300 mg once daily, In the experimental arm, the first seven days of posaconazole will be overlapped with liposomal amphotericin B 5 mg/kg body weight intravenous infusion (similar to the active comparator arm), Liposomal Amphotericin B, LAMB | Postgraduate Institute of Medical Education and Research | Mucormycosis; Pulmonary (Etiology) | 12/23 | 06/24 | | |
NCT05593666: A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis |
|
|
| Recruiting | 2 | 105 | RoW | LXE408, Placebo, AmBisome® | Drugs for Neglected Diseases, Novartis Pharmaceuticals | Primary Visceral Leishmaniasis | 01/25 | 01/25 | | |
NCT06449040: Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly |
|
|
| Completed | 1/2 | 28 | RoW | Liposomal amphotericin B (AmBisome®) | Hospital Universitário Professor Edgard Santos, Instituto Gonçalo Muniz FIOCRUZ BA | Cutaneous Leishmaniasis, American | 09/21 | 09/23 | | |
ChiCTR2000039891: Bioequivalence Study of (amphotericin B) liposome for injection in fed condition |
|
|
| Recruiting | 1 | 96 | | investigational products ;reference listed drug | Shulan (Hangzhou) Hospital; Beijing Tide Pharmaceutical Co., LTD., Beijing Tide Pharmaceutical Co.,LTD. | fungal infection; presumed fungal infection in febrile,neutropenic patients; visceral leishmaniasis | | | | |
NCT05749380: Pharmacokinetics and Safety of AmBisome and DKF-5122 |
|
|
| Completed | 1 | 38 | RoW | AmBisome, DKF-5122 | Dongkook Pharmaceutical Co., Ltd. | Invasive Fungal Infections, Neutropenic Fever | 01/22 | 01/22 | | |
| Completed | 1 | 13 | Europe | Amphotericin B Liposomal 50 MG, Ambisome, Placebo | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Invasive Pulmonary Aspergillosis | 11/22 | 11/22 | | |
NCT05913921: Bioequivalence of Amphotericin B Liposome for Injection |
|
|
| Completed | 1 | 32 | RoW | Amphotericin B liposome for injection, the test product, AmBisome, the reference product | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Bioequivalence | 09/23 | 09/23 | | |
NCT03529617: Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates |
|
|
| Recruiting | N/A | 60 | Europe | Sample collection | Universitaire Ziekenhuizen KU Leuven, KU Leuven | Pharmacokinetics, Liposomal Amphotericin B, Critically Ill Patients | 07/25 | 12/25 | | |
| Not yet recruiting | N/A | 96 | | Amphotericin B liposomes for injection, 2.0 mg/kg ;Liposome for Injection,2.0 mg/kg | Phase I Clinical Trial Department, The First Hospital of Jilin University; Jiangxi Ashter Pharmaceutical Co., Ltd., Sponsor | Empirical treatment of suspected fungal infections in febrile neutropenia patients; Treatment of cryptococcal meningitis in HIV-positive patients; Treat patients with Aspergillus, Candida and/or Crypt | | | | |
NCT06123832: Study of the Clinical Benefits of Different Formulations of Amphotericin B |
|
|
| Active, not recruiting | N/A | 184 | RoW | | Qianfoshan Hospital | Efficacy, Safety | 08/23 | 08/24 | | |
NCT04157465: Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients |
|
|
| Recruiting | N/A | 216 | RoW | Treatment strategy trial | Postgraduate Institute of Medical Education and Research | Antifungal Agents, Invasive Fungal Infections, Mycoses, Acute-On-Chronic Liver Failure | 12/23 | 06/24 | | |